If you have trouble reading this newsletter, view the web version here

   

IACH NEWS OF THE WEEK

February 8, 2026
Prepared by Dr Edwin Uriel Suárez

Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial.  

Highlights:

-        Preliminary reports suggest interim positron emission tomography (PET) could drive treatment duration in limited-stage diffuse large B-cell lymphoma (DLBCL).

-        A risk-adapted approach using early PET after two cycles of R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone) was beneficial, minimizing toxicity without compromising efficacy in patients treated in first-line therapy for low-risk DLBCL.

 

This phase III randomized trial (LNH2009-1B) in first-line therapy for DLBCL patients (18-80 years) with adjusted-age international prognostic index (aaIPI) risk=0, evaluates an experimental PET-response adapted approach (n=319) using PET response after two cycles of R-CHOP to de-escalate treatment duration; patients with a negative PET after two cycles received four cycles in total of R-CHOP, whereas those with a positive PET after two cycles received a total of six cycles. In the standard arm (n=331), treatment was six cycles regardless of PET results after two cycles. The primary endpoint was 3year progression-free survival (PFS).

 

In the PET-adapted arm, 77.7% of patients had a negative PET scan after two cycles and received a total of four cycles of R-CHOP. The 3-year PFS in PET-adapted and standard arms were 92.0% [95% confidence interval (CI) 88.3% to 94.5%] and 89.2% (95% CI 85.3% to 92.2%), respectively (P=0.070). The noninferiority of the experimental PET-adapted arm was demonstrated (hazard ratio 0.72, 95% CI 0.47-1.12, P< 0.0001). Patients in the PET-adapted arm had fewer adverse events of grades ≥3 (54.7% versus 62.7%, P=0.046) and serious adverse events (9.5% versus 14.2%, P=0.039).

Link 1 (original paper)
Link 2 (ClinicalTrial.gov)

Bone marrow transplantation for sickle cell disease using post-transplantation cyclophosphamide and 400 cGy TBI [Retrospective study and preliminary data of phase II clinical trial].  

Highlights:

-        Reduced intensity conditioning (RIC), haploidentical donors, and post-transplantation cyclophosphamide (PTCy) have overcome many barriers associated with bone marrow transplantation (BMT) for sickle cell disease (SCD). However, initial approaches had high graft failure rates.

-        RIC BMT with 400 cGy provides high rates of durable engraftment, low graft-versus-host disease (GVHD) toxicity, and may preserve fertility.

-        This regimen expands the availability of curative therapy for severe SCD.

 

This study included SCD patients aged 2-70 years undergoing BMT from November 2014–January 2025. The regimen included anti-thymocyte globulin, fludarabine, cyclophosphamide, and single fraction 400 cGy total body irradiation. GVHD prophylaxis included PTCy, mycophenolate mofetil, and sirolimus. Outcomes measured were disease-free survival (DFS), graft failure, overall survival (OS), and GVHD incidence. Forty-three patients (median age 23) were transplanted. Five-year OS probability was 95.5% (95% confidence interval [CI] 0.87 - 1.0) at a median follow-up of 2.43 years. DFS probability at 2 years was 94.5% (95% CI 0.87 - 1.0) with only 2 (5%) graft failures. Two patients died late (2.5 and 6 years) after BMT. The cumulative incidence of grades 3-4 acute GVHD was 2.4% (95% CI 0 - 0.07) and moderate-severe chronic GVHD was 7.3% (95% CI 0 - 0.15). Median time to discontinuation of immunosuppression was 354 days. Of the 27 female patients, 12 had return of menses and/or normalized gonadal function.

Link 1 (original paper)
Link 2 (ClinicalTrials.gov)

Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC/BCL2 rearrangements, DLBCL morphology [Retrospective study].

Highlights: 

-        High-grade B-cell lymphoma with "double-hit" MYC and BCL2 rearrangements (HGBCL-DH-BCL2) is associated with poor outcomes following standard chemoimmunotherapy, prompting dose-intensive regimen use. However, the benefit of intensification is unclear due to rarity precluding randomized trials and selection bias in retrospective comparisons.

-        Population-wide introduction of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) is associated with improved outcomes in HGBCL-DH-BCL2 with diffuse large B-cell lymphoma (DLBCL) morphology.

-        After DA-EPOCH-R introduction, outcomes improved most in the IG::MYC and dark-zone signature (DZsig)–positive subgroups of HGBCL-DH-BCL2.

 

The authors compared the outcomes of patients with de novo HGBCL-DH-BCL2 tumors of DLBCL morphology across 2 eras: The DA-EPOCH-R era (2015-2020) included patients diagnosed after guideline implementation (DA-EPOCH-R for fit patients aged ≤75 years with HGBCL-DH-BCL2 identified by routine cytogenetic testing). The historic era (2005-2010) included patients identified from a historic province-wide cohort of patients with DLBCL morphology tumors that underwent universal cytogenetic testing in a research setting, predominantly treated with standard chemoimmunotherapy. Two-year overall survival (OS) was significantly improved in the DA-EPOCH-R vs. historic era (75% vs. 47%, P=0.008) in HGBCL-DH-BCL2, whereas OS remained unchanged in DLBCL, not otherwise specified (78% vs. 76%, P=0.17). Within HGBCL-DH-BCL2, tumors harboring immunoglobulin MYC partner loci (43%) and those expressing the DZsig (77%) were associated with the most substantial survival improvements. In a contemporary cohort of HGBCL-DH-BCL2 histologically transformed from follicular lymphoma (FL) in the DA-EPOCH-R era, outcomes of patients who were chemoimmunotherapy-naïve were comparable to those with de novo disease, whereas patients treated with chemoimmunotherapy for FL prior to transformation had poor outcomes. 

Click for the full article

Familial clusters and clinical features, complications, and outcomes in 1000 patients with Waldenström macroglobulinemia [Retrospective study].  

Highlights:

-        Approximately 20% of patients with Waldenström macroglobulinemia (WM) report family history (FH) of hematologic malignancies.

-        Patients with WM and WM-FH had higher odds of Bing-Neel syndrome (BNS) and lower odds of peripheral neuropathy.

-        WM-FH did not affect time to first treatment (TTFT), overall survival (OS), or survival after first treatment initiation (SAFTI) in patients with WM.

 

This study included 1000 patients with WM to determine the relationship between FH, characteristics, complications, and treatment outcomes. Data collected included clinical features at diagnosis, complications, FH cluster (WM [WM-FH], other B-cell FH [B-FH], non–B-cell FH [Non-B-FH], and sporadic [NO-FH]), and treatment outcomes. The median follow-up time from diagnosis was 13 years. There were more women in the WM-FH than in the NO-FH group (50% vs. 34%; P<0.01). In multivariate logistic regression analysis, WM-FH was associated with higher odds of BNS (odds ratio [OR], 3.90; P=0.005) and lower odds of neuropathy (OR, 0.49; P=0.03) than NO-FH. The median TTFT was 0.7 years, OS was 23 years, and SAFTI was 20.5 years for all patients.

Click for the full article

Spontaneous Heparin-Induced Thrombocytopenia after Total Hip Arthroplasty [Case report; Correspondence NEJM].

Spontaneous heparin-induced thrombocytopenia (HIT) with potential thrombosis is a rare anti–platelet factor 4 (PF4) disorder that is a known complication of total knee arthroplasty despite the absence of heparin exposure. Spontaneous HIT resembles autoimmune HIT, a severe form of this disorder that features both heparin-dependent and heparin-independent platelet-activating properties.

 

A 60-year-old male patient was admitted on the 34th day post-total hip arthroplasty,  after total hip arthroplasty with saddle pulmonary embolus and extensive bilateral lower-limb deep vein thromboses. He was receiving postoperative prophylaxis with aspirin. The platelet count was 19,000 per cubic millimeter. An evaluation for hypercoagulability showed antibodies of IgG class against PF4–polyanion by chemiluminescence immunoassay. Serotonin-release assay indicated a platelet-activating anti–PF4–polyanion disorder. The absence of heparin exposure was documented in the patient’s chart, and no mention of heparin appeared in the operative note. No arterial or central lines had been placed intraoperatively, nor had any stock heparin flushes been used that would not appear in these records. The patient’s only known lifetime heparin exposure occurred during a percutaneous coronary intervention that was performed 3 years earlier without the development of HIT.

Bivalirudin anticoagulation was initiated, followed the next day by two doses of intravenous immune globulin (IVIG), administered 24 hours apart; anticoagulation was transitioned to apixaban, with a temporary increase in dose owing to a decrease in the platelet count. The platelet count normalized over several weeks. No recurrence of thrombosis was noted at the last follow-up on day 225. In order to investigate the presence of anti-PF4 antibodies with heparin-independent platelet-activating properties, a sample of the patient's plasma was referred to the McMaster Platelet Immunology Laboratory. These findings indicated the production of heparin-independent platelet-activating antibodies. Furthermore, the patient's antibodies against PF4–polyanion were investigated by fluid-phase ELISA, which confirmed greater binding against PF4–heparin than PF4 alone. This finding was consistent with the presence of autoimmune HIT.

 

A hypothesis for the development of spontaneous HIT after total knee arthroplasty is the abrupt release of an accumulation of polyanions after tourniquet removal that could have activity analogous to that of heparin, in which polyanions cause conformational changes in PF4 that permit binding to HIT antibodies. 

Click for the full article

IACH Webinars

Stay tuned for the upcoming IACH webinars

Click here

For questions please contact:
info@clinical-hematology.org


If you prefer not to receive future email communications from us, please unsubscribe here

This newsletter was sent using ITnewsletter